Previous 10 | Next 10 |
2023-11-08 11:57:02 ET More on OncoCyte Seeking Alpha’s Quant Rating on OncoCyte Historical earnings data for OncoCyte Financial information for OncoCyte For further details see: OncoCyte Q3 2023 Earnings Preview
IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discus...
Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte's VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA / ACCESSWIRE / September 18, 2023 / O...
CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA / ACCESSWIRE / September 6, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Inve...
First digital-droplet PCR assay to receive coverage Expect initial revenue generation in Q1 2024 IRVINE, CA / ACCESSWIRE / August 28, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor ...
2023-08-10 12:06:05 ET OncoCyte Corporation (OCX) Q2 2023 Earnings Conference Call August 10, 2023, 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, IR Josh Riggs - President and CEO Conference Call Participants Mike Matson - Needham &...
2023-08-10 07:05:33 ET OncoCyte press release ( NASDAQ: OCX ): Q2 GAAP EPS of -$1.03 beats by $0.21 . Revenue of $0.46M (+91.7% Y/Y) beats by $0.11M . Cash, cash equivalents, and marketable securities totaled $17.9 million at June 30, 2023, with average cash bu...
Conference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA / ACCESSWIRE / August 10, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023. Second Quarte...
2023-08-09 14:09:04 ET OncoCyte ( NASDAQ: OCX ) is scheduled to announce Q2 earnings results on Thursday, August 10th, before market open. The consensus EPS Estimate is -$0.59 (-742.9% Y/Y) and the consensus Revenue Estimate is $0.35M (-83.3% Y/Y).Over the last 3 months, EPS...
IRVINE, CA / ACCESSWIRE / August 9, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the...
News, Short Squeeze, Breakout and More Instantly...
Late-breaking presentation of data at American Transplant Congress on Monday, June 3 Data show potential to monitor for therapeutic efficacy and recurrence Potential repeat testing opportunities with claims expansion IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp...
IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Labora...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...